
    
      Subjects will receive FF-10101-01 orally once a day repeated every 28 days =1 cycle Frequent
      blood draws will be collected to measure pharmacodynamic parameters and pharmacodynamic
      activity.

      Disease assessments, including bone marrow aspirates, will be performed at the beginning of
      cycles 1-3, and every 3 months thereafter. Subjects who demonstrate objective response or
      stable disease will be allowed to continue therapy with FF-10101-01 until , observation of
      unacceptable adverse events, or until the subject is no longer deriving benefit based on the
      opinion of the investigator.

      For Phase 2a long term phone follow-up for assessment of overall survival will also occur.
    
  